Cancer Immunotherapy
Complete guide to cancer immunotherapy — checkpoint inhibitors, CAR-T therapy, cytokine therapy, and combination approaches. Understand eligibility, costs, and outcomes with Gaf Healthcare.
Estimated cost: $3,000 – $6,000 per cycle · Average stay: 1–2 days
Cancer immunotherapy represents the most significant paradigm shift in oncology since the introduction of chemotherapy. Rather than directly attacking cancer cells (as chemotherapy and radiation do), immunotherapy harnesses and amplifies the patient's own immune system to recognise and destroy cancer cells. The underlying insight — that cancer evades immune destruction through specific molecular escape mechanisms — has translated into a revolution in treatment across virtually every tumour type over the past decade.
The most clinically impactful immunotherapy modality is checkpoint inhibitor therapy — monoclonal antibodies targeting immune checkpoint proteins (PD-1, PD-L1, CTLA-4) that cancer cells exploit to suppress T-cell activity. By blocking these "off switches," checkpoint inhibitors restore T-cell killing capability, enabling durable tumour destruction. The unprecedented 5- and 10-year survival data now emerging from landmark checkpoint inhibitor trials — particularly in melanoma, lung cancer, bladder cancer, and renal cell carcinoma — represent the most dramatic survival improvements ever documented in advanced solid tumour oncology.
Beyond checkpoint inhibitors, the immunotherapy landscape includes: CAR-T cell therapy (engineering a patient's own T-cells to recognise and kill specific cancer antigens), bispecific antibodies (linking T-cells directly to cancer cells), cancer vaccines (now approved for high-risk KRAS-mutant early lung cancer via Keytruda), cytokine therapy (IL-2, IFN-α — older, less targeted), and antibody-drug conjugates (ADCs — antibodies carrying cytotoxic drug payloads to tumour cells, at the intersection of immunotherapy and chemotherapy).
Gaf Healthcare connects patients with comprehensive oncology programs offering the full spectrum of approved immunotherapy agents, with access to clinical trial programmes and compassionate use pathways for patients who have exhausted standard treatment options.
How Cancer Immunotherapy Works: Checkpoint Inhibitors, CAR-T, and Beyond
The PD-1/PD-L1 checkpoint pathway is the most clinically important immunotherapy target discovered to date. PD-L1 is expressed on cancer cells as a shield — it binds PD-1 receptors on T-cells and delivers an "off" signal that prevents T-cells from attacking. Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab) are antibodies that block either PD-1 or PD-L1, lifting this suppression and allowing cytotoxic T-cells to destroy cancer cells. The CTLA-4 checkpoint — targeted by ipilimumab — is a second pathway that regulates T-cell activation in lymph nodes; combining PD-1 and CTLA-4 blockade (nivolumab + ipilimumab) produces additive anti-tumour effects in melanoma, lung cancer, and mesothelioma.
CAR-T cell therapy is a more complex, personalised immunotherapy approach. The patient's own T-cells are collected from blood (leukapheresis), genetically engineered in a laboratory to express a Chimeric Antigen Receptor (CAR) targeting a specific cancer antigen (CD19 for B-cell malignancies, BCMA for multiple myeloma, CD22, and others), and then expanded and reinfused into the patient. CAR-T cells recognise and kill cancer cells expressing the target antigen with remarkable efficacy — achieving complete remission in a significant proportion of patients with relapsed/refractory B-cell lymphomas and multiple myeloma who have failed all prior treatments.
Tumour Mutational Burden (TMB) and microsatellite instability (MSI-H/dMMR) are predictive biomarkers for checkpoint inhibitor response across multiple tumour types: high TMB (≥10 mutations per megabase) or MSI-High status predict response to pembrolizumab regardless of histological tumour type — the basis for the first tumour-agnostic immunotherapy approvals.
Who Is a Candidate for Cancer Immunotherapy?
Immunotherapy candidacy is determined by tumour type, expression of predictive biomarkers, prior treatment history, and patient performance status.
Checkpoint inhibitor candidates include: patients with PD-L1-expressing tumours in approved indications (lung, bladder, cervical, head and neck, oesophageal, gastric, endometrial cancers); all tumour types with MSI-H/dMMR or high TMB (≥10 mut/Mb); melanoma (checkpoint inhibitors are first-line regardless of PD-L1); renal cell carcinoma (combination nivolumab + ipilimumab, or PD-1 + TKI combinations); and classical Hodgkin lymphoma (pembrolizumab or nivolumab after failure of auto-SCT or brentuximab vedotin).
Pre-treatment biomarker testing is mandatory before checkpoint inhibitor selection: PD-L1 immunohistochemistry (TPS and CPS scoring), MSI testing (PCR or IHC), TMB if approved tissue NGS panel available, and specific tumour histology confirmation.
CAR-T cell therapy candidates: relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after ≥2 prior lines of treatment; relapsed/refractory follicular lymphoma; relapsed/refractory mantle cell lymphoma; relapsed/refractory B-cell ALL in adults; and relapsed/refractory multiple myeloma after ≥4 prior lines. Eligibility requires adequate organ function, no active CNS disease (for most indications), and performance status ECOG 0–2.
Contraindications to checkpoint inhibitors include: active autoimmune disease requiring systemic immunosuppressive therapy (risk of severe immune-related adverse events); solid organ transplant recipients (risk of allograft rejection); and active corticosteroid therapy above 10 mg prednisone equivalent per day.
How Immunotherapy Is Administered
Checkpoint inhibitors are administered by intravenous infusion in an outpatient infusion suite. Pembrolizumab is given every 3 or 6 weeks (200 mg Q3W or 400 mg Q6W); nivolumab every 2 or 4 weeks; atezolizumab every 3 or 4 weeks. Infusions take 30–60 minutes. The outpatient nature is a significant quality-of-life advantage over inpatient chemotherapy.
Monitoring for immune-related adverse events (irAEs) — the characteristic toxicities of checkpoint inhibitors — requires patient education and vigilant clinical surveillance. irAEs can affect any organ system — commonly skin (rash, vitiligo), gut (colitis), liver (hepatitis), lung (pneumonitis), thyroid (thyroiditis, hypothyroidism), and adrenal glands (adrenal insufficiency). Most are manageable with systemic corticosteroids and immunosuppressive therapy. Severe irAEs require permanent drug discontinuation in some cases.
CAR-T cell therapy involves: leukapheresis (T-cell collection, 2–4 hours); manufacturing phase (2–4 weeks in the laboratory); lymphodepleting chemotherapy (fludarabine + cyclophosphamide, 3 days); CAR-T cell infusion (Day 0); and intensive in-patient monitoring for 2–4 weeks for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). CAR-T therapy is currently administered only at certified treatment centres with specific CAR-T competency.
Procedure Steps
- Biomarker testing: PD-L1 IHC, MSI/MMR testing, TMB (if applicable), tumour NGS; results required before checkpoint inhibitor selection.
- Baseline assessment: organ function tests; imaging for baseline disease measurement; thyroid, adrenal, and pituitary function.
- For checkpoint inhibitors: IV infusion administration in outpatient oncology suite; vital signs monitoring during infusion.
- Clinical response assessment by CT/PET-CT every 8–12 weeks; immune-related adverse event surveillance at every visit.
- Management of irAEs: early steroid initiation for grade ≥2 irAEs; specialist input (gastroenterology, pulmonology, endocrinology) for organ-specific events.
- For CAR-T: patient registration at certified centre; leukapheresis for T-cell collection; manufacturing (2–4 weeks).
- Lymphodepleting chemotherapy (flu/cy) Days -5 to -3; CAR-T cell infusion Day 0.
- ICU-level monitoring for CRS and ICANS; tocilizumab and corticosteroids as CRS management; neurological assessment daily.
Types of Cancer Immunotherapy
PD-1 / PD-L1 Checkpoint Inhibitors
Pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab — administered by IV infusion every 2–6 weeks. First-line or subsequent-line treatment for a growing list of solid tumours. Durable responses seen in a significant minority of patients — some achieving long-term disease control for years. Best response in high PD-L1 tumours, MSI-H, or high TMB.
Cost: $2,000 – $8,000 per infusion
CTLA-4 Checkpoint Inhibitor (Ipilimumab)
Ipilimumab targets the CTLA-4 checkpoint — a different regulatory mechanism from PD-1. Most commonly used in combination with nivolumab (CheckMate trials) in advanced melanoma, lung cancer, renal cell carcinoma, and mesothelioma. Combination immunotherapy provides deeper and more durable responses than either agent alone, at the cost of higher immune-related toxicity.
Cost: $4,000 – $15,000 per infusion (higher dose for combination)
CAR-T Cell Therapy
Personalised T-cell engineering against specific cancer antigens (CD19, BCMA, CD22). A single-course treatment for relapsed/refractory B-cell lymphomas (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel) and multiple myeloma (ciltacabtagene autoleucel, idecabtagene vicleucel). Complete remission rates of 40–90% in heavily pre-treated populations previously considered incurable. Manufacturing and administration must occur at certified centres.
Cost: $250,000 – $500,000 (one-time treatment)
Antibody-Drug Conjugates (ADCs)
Monoclonal antibodies linked to a potent cytotoxic drug payload, delivered selectively to cancer cells expressing the target antigen. Precision medicine combining immunological targeting with chemotherapy lethality. Examples: trastuzumab deruxtecan (HER2-targeted), enfortumab vedotin (nectin-4, bladder cancer), sacituzumab govitecan (Trop-2, triple-negative breast cancer). Rapidly expanding class with dramatic efficacy signals in multiple tumour types.
Cost: $3,000 – $12,000 per infusion
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
United States — $150,000 – $500,000 per year — Baseline
United Kingdom — $50,000 – $150,000 per year — ~70% vs. USA
Germany — $40,000 – $130,000 per year — ~73% vs. USA
India — $10,000 – $40,000 per year — Up to 90% vs. USA
UAE — $40,000 – $120,000 per year — ~70% vs. USA
Checkpoint inhibitors are among the most expensive medications in oncology. In the United States, pembrolizumab Q3W costs approximately $13,000 per infusion — approximately $170,000 per year for a patient receiving it every 3 weeks. For many patients, immunotherapy continues for 2 years (or until progression). Biosimilar pembrolizumab and nivolumab are commercially available at internationally approved oncology programs at dramatically lower cost. CAR-T cell therapy — a one-time treatment — costs $400,000–$500,000 in the United States; access at internationally accredited centres remains limited but is expanding.
Gaf Healthcare advises patients on the cost of both the acute treatment episode and the prolonged ongoing treatment phase, and facilitates access to immunotherapy programs that are clinically appropriate and financially accessible.
Recovery & Follow-up
Immunotherapy recovery is substantially different from chemotherapy recovery. Most patients receiving checkpoint inhibitors maintain quality of life far better than patients on cytotoxic chemotherapy — because immunotherapy spares healthy dividing cells (hair follicles, gastrointestinal epithelium) that chemotherapy destroys. Fatigue, the most common side effect, is usually mild-to-moderate. Many patients continue normal work and daily activities during treatment.
The main recovery challenge is monitoring for immune-related adverse events — which can develop at any time, including months after treatment completion. Patients require education about warning symptoms and clear guidance on when to seek urgent care. Most irAEs are effectively managed with prompt corticosteroid treatment.
CAR-T recovery requires 2–4 weeks of inpatient monitoring for CRS and ICANS, followed by several months of outpatient monitoring for delayed neurotoxicity, cytopenia, and B-cell aplasia (ongoing hypogammaglobulinaemia requiring prophylactic IVIG supplementation).
Recovery Tips
- Learn the warning signs of immune-related adverse events: new rash, severe diarrhoea, cough or breathlessness, jaundice, or severe fatigue — seek medical assessment immediately.
- Do not take corticosteroids (including over-the-counter anti-inflammatory medications) without first consulting your oncologist — they may mask irAEs.
- Maintain regular blood tests and thyroid function monitoring — immunotherapy-induced thyroid disorders are common and easily managed once identified.
- Inform all healthcare providers (GP, dentist, any emergency team) that you are receiving immunotherapy — they must be aware when evaluating any new symptoms.
- Stay hydrated and maintain nutrition; fatigue during immunotherapy is real and managed with pacing, gentle exercise, and adequate caloric intake.
- For CAR-T patients: do not drive or operate machinery for the first 8 weeks — neurotoxicity can present as subtle confusion or reaction time impairment.
- Report any new neurological symptoms during or after CAR-T therapy immediately — ICANS can progress rapidly and requires urgent assessment.
- Attend all scheduled imaging and response assessment appointments — early detection of disease progression enables timely treatment modification.
Risks & Complications
Checkpoint inhibitor toxicity is immune-mediated and differs from chemotherapy toxicity. Immune-related adverse events (irAEs) can affect any organ — colitis (diarrhoea), pneumonitis (lung inflammation), hepatitis, endocrinopathies (thyroid, adrenal, pituitary failure), nephritis, skin reactions, and rarely myocarditis or neurological events. Most irAEs resolve with corticosteroids; severe grade 3–4 events require hospital admission and high-dose methylprednisolone. Immune-related myocarditis is rare (<1%) but carries high mortality if not promptly identified and treated.
CAR-T therapy risks include cytokine release syndrome (CRS) — a systemic inflammatory response from rapid T-cell expansion and cytokine release; graded 1–4; managed with tocilizumab (IL-6 inhibitor) and corticosteroids. Immune effector cell-associated neurotoxicity syndrome (ICANS) — confusion, language difficulty, tremor — occurs in 20–60% of patients depending on the product. Prolonged cytopenias and B-cell aplasia with hypogammaglobulinaemia require long-term monitoring and IVIG supplementation.
Why GAF Healthcare
Access to approved immunotherapy agents — particularly newer combinations and CAR-T products — varies significantly between healthcare systems and markets. Gaf Healthcare maps available immunotherapy access at partner oncology programmes and helps patients understand which approved agents are accessible, which are in clinical trials, and which compassionate use pathways may be available. Our oncology coordinators review your case with the treating oncology team before travel to confirm that your specific indication and treatment is available and ready to initiate.
Frequently Asked Questions
How do I know if my cancer will respond to immunotherapy?
Biomarker testing predicts which patients are most likely to respond. High PD-L1 expression on tumour cells, MSI-H/dMMR status (present in approximately 5–30% of various tumour types), and high tumour mutational burden (≥10 mutations/megabase) are all associated with better response to checkpoint inhibitors. However, even PD-L1-negative tumours can respond, and some PD-L1-high tumours do not — biomarkers predict probability, not certainty. Comprehensive tumour profiling before treatment selection is essential.
How is immunotherapy different from chemotherapy?
Chemotherapy directly kills rapidly dividing cells — both cancer cells and healthy dividing cells (hair follicles, gastrointestinal epithelium, bone marrow). Immunotherapy does not directly kill cells; instead, it removes the cancer's ability to hide from the immune system, enabling the patient's own T-cells to recognise and destroy tumour cells. As a result, immunotherapy typically causes far less nausea, hair loss, and bone marrow suppression than chemotherapy. Its toxicities are immune-mediated (inflammation in healthy organs), which are usually manageable but can occasionally be severe.
Can immunotherapy cure cancer?
For a subset of patients, checkpoint inhibitor immunotherapy produces complete and durable responses that outlast the treatment itself — effectively representing cures in some cases. In advanced melanoma, approximately 20–25% of patients who received ipilimumab in initial trials are alive 10+ years later with no evidence of disease — most would have survived only months without treatment. Similar durable complete response rates are emerging in lung cancer, renal cell carcinoma, and Hodgkin lymphoma. For most patients, immunotherapy extends survival and controls disease rather than curing it.
What is CAR-T therapy and who can receive it?
CAR-T therapy involves collecting your own T-cells (from a blood draw), genetically engineering them to recognise specific proteins on your cancer cells, growing them in large numbers, and infusing them back. Currently approved for relapsed or refractory B-cell lymphomas (after ≥2 prior treatments), multiple myeloma (after ≥4 prior treatments), and B-cell ALL in adults. It is a highly specialised treatment performed only at certified CAR-T centres with specific infrastructure for manufacturing, administration, and toxicity management.
How long does immunotherapy treatment continue?
For checkpoint inhibitors, the standard treatment duration in most approved protocols is 2 years (35 cycles of Q3W pembrolizumab, for example). After 2 years of treatment without progression, therapy is typically stopped. Long-term responders who complete 2 years maintain durable responses in many cases — studies show that stopping pembrolizumab after 2 years does not significantly compromise survival outcomes compared to continuing indefinitely. For CAR-T therapy, it is a single infusion — no ongoing treatment administration is required.
Are immunotherapy drugs available as generics or biosimilars?
Biosimilar pembrolizumab and nivolumab — biologics manufactured to be highly similar to the original reference products — are now approved by regulatory agencies in several jurisdictions and used at internationally accredited oncology programs. Clinical trials have confirmed equivalent efficacy and safety between biosimilar and reference checkpoint inhibitors. Access to biosimilar immunotherapy agents is a significant driver of cost reduction at internationally accredited programs compared to US pricing of the reference products.